Early Right Cardiac Dysfunction in Patients with Schistosomiasis Mansoni

Carvalho, Vinicius Tostes; Barbosa, Márcia M.; Nunes, Maria Carmo Pereira; Cardoso, Yuri; Filho, Isaías M. de Sá; Oliveira, Flávio Roberto Azevedo de; Antunes, Carlos; Lambertucci, José Roberto

doi:10.1111/j.1540-8175.2010.01330.x

Cited by 7 publications

(2 citation statements)

References 30 publications

(87 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chronic intestinal (also referred as hepatointestinal) schistosomiasis, defined as the presence of parasites in the stool without portal hypertension, as well as chronic hepatosplenic schistosomiasis, defined as the presence of parasites in the stool with portal hypertension and usually periportal fibrosis (with or without splenomegaly), are mainly caused by S. japonicum and S. mansoni. [13][14][15] S. haematobium, on the other hand, can cause chronic genitourinary disease. Extrapulmonary clinical manifestations of the disease are summarized in Table 1.…”

Section: Schistosoma Life Cyclementioning

confidence: 99%

Schistosomiasis‐Associated Pulmonary Hypertension

et al. 2014

View full text Add to dashboard Cite

Schistosomiasis, a parasite-borne disease, is highly prevalent in Africa and Asia; it is estimated that close to 20 million people worldwide have a severe form of the disease. The chronic form can affect the gastrointestinal system and lead to hepatosplenic disease, and it may cause cardiopulmonary complications, including pulmonary hypertension. The exact pathogenesis of schistosomiasis-associated pulmonary hypertension (Sch-PH) remains unclear, although several mechanisms, including parasitic arterial embolization, pulmonary arteriopathy, and portopulmonary hypertension-like pathophysiology, have been suggested. The immunopathology of the disease is also unclear, although there are similarities with the immunology of idiopathic pulmonary arterial hypertension (PAH). Finally, the treatment of Sch-PH has not been well studied. There is some evidence on treating the underlying infection, with unclear effect on Sch-PH, and advanced PAH therapies are now being suggested, but more studies are needed to confirm their efficacy.

show abstract

Section: Schistosoma Life Cyclementioning

confidence: 99%

Schistosomiasis‐Associated Pulmonary Hypertension

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Schistosomal pulmonary hypertension is diagnosed in approximately 10% of the patients with hepatosplenic schistosomiasis [48][49][50][51] ; the use of pulmonary vasodilators has greatly improved the survival and quality of life of those patients [52][53][54][55] .…”

Section: Complications Of Hepatosplenic Schistosomiasismentioning

confidence: 99%

Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools

Lambertucci

2014

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Different aspects of hepatosplenic schistosomiasis are revisited here. Manson's schistosomiasis causes periportal fi brosis and portal hypertension in approximately 6% of infected subjects, usually with preservation of their hepatic function. The assessment of liver involvement is of major importance in determining the prognosis and risk of complications from schistosomiasis, such as upper digestive bleeding secondary to variceal rupture. For many years, the diagnosis of hepatosplenic schistosomiasis and liver fi brosis was made by abdominal palpation and the fi nding of liver and/or spleen enlargement. However, there is no consensus regarding the clinical parameters of the liver and spleen to be considered in this physical evaluation. For the last three decades, abdominal ultrasound (US) has become the best imaging technique to evaluate liver fi brosis caused by schistosomiasis mansoni. However, US is a subjective procedure and is therefore examiner-dependent. Magnetic resonance imaging (MRI) fi ndings have provided valuable information in addition to ultrasound and clinical examination. The combination of a comprehensive history and physical examination, basic laboratory tests (a stool examination for Schistosoma mansoni eggs and a blood cell count), biomarkers for liver fi brosis/portal hypertension and imaging methods seem to offer the best approach for evaluating patients with this disease. In situations where research is involved or in patients with severe disease, MRI may be considered.

show abstract

The chronic enteropathogenic disease schistosomiasis

Olveda¹,

Olveda

McManus

et al. 2014

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Schistosomiasis is a chronic enteropathogenic disease caused by blood flukes of the genus Schistosoma. The disease afflicts approximately 240 million individuals globally, causing approximately 70 million disability-adjusted life years lost. Chronic infections with morbidity and mortality occur as a result of granuloma formation in the intestine, liver, or in the case of Schistosoma haematobium, the bladder. Various methods are utilized to diagnose and evaluate liver fibrosis due to schistosomiasis. Liver biopsy is still considered the gold standard, but it is invasive. Diagnostic imaging has proven to be an invaluable method in assessing hepatic morbidity in the hospital setting, but has practical limitations in the field. The potential of non-invasive biological markers, serum antibodies, cytokines, and circulating host microRNAs to diagnose hepatic fibrosis is presently undergoing evaluation. This review provides an update on the recent advances made with respect to gastrointestinal disease associated with chronic schistosomiasis.

show abstract

Early Right Cardiac Dysfunction in Patients with Schistosomiasis Mansoni

Abstract: Larger RAA and RVEDA were found in patients with hepatosplenic SM, when compared to patients with the hepatointestinal form, which may suggest early impairment of RV function in patients with hepatosplenic SM.

Cited by 7 publications

References 30 publications

Schistosomiasis‐Associated Pulmonary Hypertension

Schistosomiasis‐Associated Pulmonary Hypertension

Revisiting the concept of hepatosplenic schistosomiasis and its challenges using traditional and new tools

The chronic enteropathogenic disease schistosomiasis

Contact Info

Product

Resources

About